In the subsequent SURMOUNT-2 trial, tirzepatide was studied in patients with diabetes and 79-83% patients achieved 5% weight loss or more on the 10 or 15 mg dose.3 Comparatively, patients receiving semaglutide 2.4 mg (the highest dose studied) achieved 5% weight loss or more in 86.4% patients without diabetes4 and in only 68.8% patients with diabetes.5 It is tempting to conclude that male patients with type 2 diabetes may have a better chance of achieving weight loss goals with tirzepatide rather than semaglutide based on these data
Peptide therapy in Austin, TX offers targeted support for goals like metabolic balance, body composition, hormone optimization, and healthy aging
Our team serves patients across Arlington, Richardson, Dallas, and Texarkana, TX
Funding We are grateful for the support by grants National Natural Science Foundation of China (82160162, 81760150) and key project of Jiangxi Provincial Natural Science Foundation (20202ACBL206008)
However, possession of research chemicals for personal use generally does not carry the same legal consequences as controlled substances
the standard monthly tiers are roughly twice that